#MSD's return to the #ophthalmology field after decades of absence, via the #acquisition of #EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in #diabeticmacularoedema (DME).
pharmaphorum.com/news/wnt-dru...
pharmaphorum.com/news/wnt-dru...
Wnt drug gives MSD first eye disease win after EyeBio deal
MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
pharmaphorum.com
September 25, 2026 at 9:22 AM
#MSD's return to the #ophthalmology field after decades of absence, via the #acquisition of #EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in #diabeticmacularoedema (DME).
pharmaphorum.com/news/wnt-dru...
pharmaphorum.com/news/wnt-dru...
#Ophthalmology #BoehringerIngelheim #diabeticeyedisease #diabeticmacularoedema #DME #BI1815368 #THULITEstudy #centreinvolvedDME #VEGFtargetingdrugs #Roche #Vabysmo #faricimab #Lucentis #ranibizumab #Bayer #Regeneron #Eylea #aflibercept #Susvimo #ranibizumab
pharmaphorum.com/news/boehrin...
pharmaphorum.com/news/boehrin...
Boehringer raises hope of oral drug for diabetic eye disease
Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.
pharmaphorum.com
July 11, 2025 at 8:32 AM
People living with #diabeticmacularoedema (DME) currently have to undergo regular injections into their #eyes to treat the condition, but an oral alternative may be on the horizon.
buff.ly/4dKxklA
buff.ly/4dKxklA
July 8, 2025 at 1:00 PM
People living with #diabeticmacularoedema (DME) currently have to undergo regular injections into their #eyes to treat the condition, but an oral alternative may be on the horizon.
buff.ly/4dKxklA
buff.ly/4dKxklA